New research on the scalable generation of universal platelets from iPSCS.
MARLBOROUGH, Mass., October 17, 2014--Advanced Cell Technology, Inc. (OTCBB: ACTC) says a new study shows that its proprietary iPSC Platelet technology is potentially capable of producing large-scale quantities of universal donor platelets for transfusion in almost any patient.
The research published online by ACT scientists and their colleagues shows that it is feasible to generate megakaryocytes and platelets from iPSCs in a scalable manner under feeder-free defined conditions.
Universal platelets were generated by removing a gene essential to expression of the major histocompatibility (HLA) antigens, which are the main molecules responsible for cell and organ rejection.
The platelets generated using this technology are functional and display features that were indistinguishable from those of human blood platelets.
The proprietary iPSC technology incorporates several discreet intermediate cells including proprietary "hemogenic endothelium like" cells.
Unlike platelets this technology allows for long tenu storage of cell material to be available and ready for transfusion within a few days when needed to produce large quantities of platelets from fully differentiated cells.
Unlike other sources of platelets, company officials said, human Induced Pluripotent Stem Cells can be propagated indefinitely, providing a potentially unlimited source of cells for therapeutic purposes.
This study shows that platelets may be produced from iPS cells without the need for serum and feeders and thus removes potential risks associated with contaminants and pathogens.
The platelets generated with our technology are functional and behave like normal human platelets. This technology and these results represent an important step towards generating unlimited supplies of universal donor platelets for transfusion.
Platelets play a critical role in stimulating clot formation, repair of vascular injury and wound healing. The current supply of platelets is limited due to their short five (5) day storage time. Low platelet levels can occur in patients as a result of trauma, chemotherapy, radiation treatment, or organ transplant surgery, among other reasons.
"Our iPSC platelet technology has the potential to overcome platelet shortages and possibly provide a readily available treatment to millions of patients," said CEO Paul K. Wotton.
To read the article, click on the following link.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Advanced Stem Cell Technology|
|Publication:||Stem Cell Lab World|
|Date:||Oct 20, 2014|
|Previous Article:||Cardio3 biosciences discusses new business development strategy.|
|Next Article:||Technology turns hESCS into billions of human insulin-producing cells.|